What are the current limitation with clinical trials for AML? This review discusses trial end points, patient enrollment, cost of drug discovery and patient heterogeneity and future treatment of AML.
Browsing: Taxonomy > Clinical trials
A team of investigators on the Head Start III trial have highlighted that patients with reduced radiotherapy experience a worse prognosis following deviations from the treatment protocol.
In this editorial from Melanoma Management the authors examine melanoma clinical trials with a focus upon targeted therapies and melanoma vaccines.
Phase I data indicate that nivolumab significantly increases long-term survival in previously treated, advanced non-small-cell lung cancer.
In this special report from Future Oncology the authors review the current literature on early salvage radiotherapy post-prostatectomy and provide key insights on the future of this therapy.
To mark Triple-Negative Breast Cancer Day, take a look at our new and exclusive summary infographic presenting some of the key facts about triple-negative breast cancer.
Researchers have identified a novel potential therapeutic target for an aggressive form of pediatric glioma.
To mark Rare Disease Day, Oncology Central brings you an exclusive opinion piece written by two of the principal investigators of a pivotal immunotherapy clinical trial designed specifically for rare cancer patients.
James Gulley of the National Cancer Institute talks to us about his work developing cancer immunotherapies, his insights into the impact of this modality in prostate cancer and his hopes for the future of the field.